CNXU

Conexeu Sciences Inc.

Price Chart

Latest Quote

$13.28

+0.26 (+2.00%)

Current Price

Previous Close	$13.02
Open	$13.25
Day High	$13.46
Day Low	$12.05
Volume	36,150

Fetched: 2026-06-20T09:34:29

Stock Information

Shares Outstanding	26.76M
Total Debt	$4K
Cash Equivalents	$6.26M
Net Income	$-5.35M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$355.35M
EPS (TTM)	$-0.34
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$255.62M
Income	$-5.35M
Book/sh	$0.34
Cash/sh	$0.23

Financial Ratios

Quick Ratio	7.14
Current Ratio	8.51
Debt/Eq	0.06

Returns & Margins

Ownership

Insider Ownership	40.98%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

38.60

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$13.58
RSI	54.95
ATR	2.2764

Shares Float	20.09M
Short Ratio	0.46
Rel Volume	0.40

Performance History

Week	+9.48%
YTD	+1.61%
10 Years	+1.61%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$13.28	36,200
2026-06-17	$13.02	61,400
2026-06-16	$12.52	123,600
2026-06-15	$9.82	91,200
2026-06-12	$11.29	58,400
2026-06-11	$12.13	78,500
2026-06-10	$13.02	56,800
2026-06-09	$13.94	84,200
2026-06-08	$15.27	90,200
2026-06-05	$15.24	35,400
2026-06-04	$16.00	76,900
2026-06-03	$16.85	154,300
2026-06-02	$16.84	288,700
2026-06-01	$14.12	285,400
2026-05-29	$11.73	29,000
2026-05-28	$11.58	46,700
2026-05-27	$13.63	42,400
2026-05-26	$13.77	45,400
2026-05-22	$14.40	31,800
2026-05-21	$13.07	87,900

About Conexeu Sciences Inc.

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

📰 Latest News

Is Conexeu Sciences (CNXU) Quietly Redefining Its Commercial Ambitions With CXU Platform Moves?

Simply Wall St. • 2026-06-19T06:16:12Z

Before the IPO: 4 Companies That Rewarded Investors Who Got In Early

MarketBeat • 2026-06-04T14:50:00Z

How Investors Are Reacting To Conexeu Sciences (CNXU) 3D-Printed Bioregenerative Breast Matrix Initiative

Simply Wall St. • 2026-06-02T10:10:42Z

Period:

Income Statement (Annual)

Metric	2025-10-31	2024-10-31
Revenue
Total Revenue	$0	$0
Operating Revenue	$0	$0
Expenses
Interest Expense	$4,949	$16,505
Total Expenses	$3,958,329	$643,042
Other Income Expense	$42,107	$188,521
Other Non Operating Income Expenses	$43,176	$218,383
Net Non Operating Interest Income Expense	$-7,335	$-17,346
Total Other Finance Cost	$4,117	$841
Interest Expense Non Operating	$4,949	$16,505
Operating Expense	$3,958,329	$643,042
Other Operating Expenses	$215,033	$42,352
Selling And Marketing Expense	$54,389	$10,461
General And Administrative Expense	$3,398,958	$352,500
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-3,923,557	$-471,867
Net Interest Income	$-7,335	$-17,346
Interest Income	$1,731	$0
Normalized Income	$-3,922,488	$-442,005
Net Income From Continuing And Discontinued Operation	$-3,923,557	$-471,867
Total Operating Income As Reported	$-3,962,446	$-643,883
Net Income Common Stockholders	$-3,923,557	$-471,867
Net Income	$-3,923,557	$-471,867
Net Income Including Noncontrolling Interests	$-3,923,557	$-471,867
Net Income Continuous Operations	$-3,923,557	$-471,867
Pretax Income	$-3,923,557	$-471,867
Special Income Charges	$0	$-35,232
Interest Income Non Operating	$1,731	$0
Operating Income	$-3,958,329	$-643,042
Depreciation Amortization Depletion Income Statement	$17,250	$0
Depreciation And Amortization In Income Statement	$17,250	$0
Amortization Of Intangibles Income Statement	$9,819	$0
Depreciation Income Statement	$7,431	$0
Per Share
Diluted EPS	$-0.19	$-0.02
Basic EPS	$-0.19	$-0.02
Other
Tax Effect Of Unusual Items	$0	$0
Tax Rate For Calcs	$0	$0
Normalized EBITDA (Bullshit earnings)	$-3,900,289	$-425,500
Total Unusual Items	$-1,069	$-29,862
Total Unusual Items Excluding Goodwill	$-1,069	$-29,862
Reconciled Depreciation	$17,250	$0
EBITDA (Bullshit earnings)	$-3,901,358	$-455,362
EBIT	$-3,918,608	$-455,362
Diluted Average Shares	$20,916,173	$20,916,173
Basic Average Shares	$20,916,173	$20,916,173
Diluted NI Availto Com Stockholders	$-3,923,557	$-471,867
Tax Provision	$0	$0
Gain On Sale Of Security	$-1,069	$5,370
Amortization	$9,819	$0
Research And Development	$272,699	$237,729
Selling General And Administration	$3,453,347	$362,961
Other Gand A	$1,119,081	$78,642
Insurance And Claims	$8,296	$0
Salaries And Wages	$2,271,581	$273,858
Other Special Charges	-	$35,232

Fetched: 2026-06-14

Balance Sheet (Annual)

Metric	2025-10-31	2024-10-31
Assets
Net Tangible Assets	$7,175,809	$-91,739
Total Assets	$7,688,711	$533,940
Total Non Current Assets	$230,298	$186,703
Non Current Deferred Assets	$42,177	$0
Goodwill And Other Intangible Assets	$176,884	$186,703
Other Intangible Assets	$176,884	$186,703
Current Assets	$7,458,413	$347,237
Restricted Cash	$25,155	$0
Prepaid Assets	$549,930	$32,621
Receivables	$2,074,363	$0
Other Receivables	$2,000,000	-
Taxes Receivable	$3,037	$0
Notes Receivable	$71,326	$0
Cash Cash Equivalents And Short Term Investments	$4,808,965	$314,616
Cash And Cash Equivalents	$4,808,965	$314,616
Cash Financial	$4,808,965	-
Debt
Total Debt	-	$98,117
Long Term Debt And Capital Lease Obligation	-	$98,117
Long Term Debt	-	$98,117
Liabilities
Total Liabilities Net Minority Interest	$336,018	$438,976
Total Non Current Liabilities Net Minority Interest	$0	$98,117
Current Liabilities	$336,018	$340,859
Payables And Accrued Expenses	$336,018	$340,859
Interest Payable	$0	$13,923
Payables	$336,018	$326,936
Other Payable	$76,000	-
Accounts Payable	$256,296	$319,024
Equity
Common Stock Equity	$7,352,693	$94,964
Total Equity Gross Minority Interest	$7,352,693	$94,964
Stockholders Equity	$7,352,693	$94,964
Retained Earnings	$-4,521,520	$-597,963
Other
Ordinary Shares Number	$20,916,173	$20,916,173
Share Issued	$20,916,173	$20,916,173
Tangible Book Value	$7,175,809	$-91,739
Invested Capital	$7,352,693	$193,081
Working Capital	$7,122,395	$6,378
Total Capitalization	$7,352,693	$193,081
Additional Paid In Capital	$11,855,307	$684,399
Capital Stock	$18,906	$8,528
Common Stock	$18,906	$8,528
Preferred Stock	$0	$0
Current Accrued Expenses	$0	$13,923
Dueto Related Parties Current	$3,722	$7,912
Net PPE	$11,237	$0
Accumulated Depreciation	$-7,431	$0
Gross PPE	$18,668	$0
Machinery Furniture Equipment	$18,668	$0

Fetched: 2026-06-14

Cash Flow Statement (Annual)

Metric	2025-10-31	2024-10-31
Free Cash Flow
Free Cash Flow	$-1,688,643	$-225,439
Operating Activities
Operating Cash Flow	$-1,669,975	$-225,439
Cash Flow From Continuing Operating Activities	$-1,669,975	$-225,439
Operating Gains Losses	-	$35,232
Investing Activities
Capital Expenditure	$-18,668	-
Investing Cash Flow	$-89,994	$0
Cash Flow From Continuing Investing Activities	$-89,994	$0
Net Other Investing Changes	$-71,326	-
Financing Activities
Issuance Of Capital Stock	$6,423,957	$531,000
Financing Cash Flow	$6,283,384	$534,637
Cash Flow From Continuing Financing Activities	$6,283,384	$534,637
Net Other Financing Charges	$-46,367	$3,637
Net Common Stock Issuance	$6,423,957	$531,000
Common Stock Issuance	$6,423,957	$531,000
Other
Repayment Of Debt	$-94,206	$0
Interest Paid Supplemental Data	$17,547	$0
Income Tax Paid Supplemental Data	$0	$0
End Cash Position	$4,834,120	$314,616
Beginning Cash Position	$314,616	$0
Effect Of Exchange Rate Changes	$-3,911	$5,418
Changes In Cash	$4,523,415	$309,198
Net Issuance Payments Of Debt	$-94,206	$0
Net Long Term Debt Issuance	$-94,206	$0
Long Term Debt Payments	$-94,206	$0
Net PPE Purchase And Sale	$-18,668	$0
Purchase Of PPE	$-18,668	$0
Change In Working Capital	$97,588	$422,571
Change In Payables And Accrued Expense	$165,423	$452,017
Change In Payable	$165,423	$452,017
Change In Account Payable	$89,423	$452,017
Change In Prepaid Assets	$-64,798	$-29,446
Change In Receivables	$-3,037	$0
Other Non Cash Items	$794,368	$-218,182
Stock Based Compensation	$1,344,376	$6,807
Depreciation Amortization Depletion	$17,250	$0
Depreciation And Amortization	$17,250	$0
Amortization Cash Flow	$9,819	$0
Amortization Of Intangibles	$9,819	$0
Depreciation	$7,431	$0
Net Income From Continuing Operations	$-3,923,557	$-471,867

Fetched: 2026-06-14